Skip to main content

Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis



Duchenne Muscular Dystrophy (DMD) is a rare disorder caused by mutations in the dystrophin gene. A recent systematic review and meta-analysis of global DMD epidemiology is not available. This study aimed to estimate the global overall and birth prevalence of DMD through an updated systematic review of the literature.


MEDLINE and EMBASE databases were searched for original research articles on the epidemiology of DMD from inception until 1st October 2019. Studies were included if they were original observational research articles written in English, reporting DMD prevalence and/or incidence along with the number of individuals of the underlying population. The quality of the studies was assessed using a STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist adapted for observational studies on rare diseases. To derive the pooled epidemiological prevalence estimates, a meta-analysis was performed using random-effects logistic models for overall and birth prevalence and within two different underlying populations (i.e. all individuals and in males only), separately. Heterogeneity was assessed using Cochran’s Q-test along with its derived measure of inconsistency I2.


A total of 44 studies reporting the global epidemiology of DMD were included in the systematic review and only 40 were included in the meta-analysis. The pooled global DMD prevalence was 7.1 cases (95% CI: 5.0–10.1) per 100,000 males and 2.8 cases (95% CI: 1.6–4.6) per 100,000 in the general population, while the pooled global DMD birth prevalence was 19.8 (95% CI:16.6–23.6) per 100,000 live male births. A very high between-study heterogeneity was found for each epidemiological outcome and for all underlying populations (I2 > 90%). The test for funnel plot asymmetry suggested the absence of publication bias. Of the 44 studies included in this systematic review, 36 (81.8%) were assessed as being of medium and 8 (18.2%) of low quality, while no study was assessed as being of high quality.


Generating epidemiological evidence on DMD is fundamental to support public health decision-making. The high heterogeneity and the lack of high quality studies highlights the need to conduct better quality studies on rare diseases.


Duchenne Muscular Dystrophy (DMD) is a rare neuromuscular X-linked disorder that belongs to a group of disorders known as dystrophinopathies. DMD is caused by mutations in the dystrophin gene that lead to the absence of dystrophin or structural defects of this protein. The lack of functional dystrophin in turn impairs the structure and function of myofibres which are essential for physiological growth of muscle tissue [1]. Due to the localization of the dystrophin gene on the X chromosome, DMD predominantly affects male children, while females are likely to be asymptomatic “healthy carriers” [2].

DMD is characterized by a progressive degeneration of skeletal muscles, with symptoms that manifest early, at around 3 years, causing loss of ambulation within the 13 year of life, followed by cardiac complications (e.g. dilated cardiomyopathy and arrhythmia) and respiratory disorders, including chronic respiratory failure [3]. In the first phase of the disease, the child experiences difficulty in running, climbing stairs, jumping, getting up from the ground, falls frequently and develops a wadding gait with a positive “Gowers’ sign” [1]. The subsequent impairment of the cardiac and respiratory systems is the main cause of death for these patients. Survival is linked to cardiac involvement and has greatly improved thanks to the use of nocturnal ventilation and spinal surgery, with 30% patients surviving beyond 30 years of age [4] and a median survival improved to 30 years [5]. A proportion of DMD patients also experience behavioral and cognitive impairment with intellectual disability, attention hyperactivity disorder (ADHD) and autism spectrum disorders [6]. The disease burden and economic costs are very high and dramatically increase with disease progression [7]. The different burden of comorbidity and mortality in DMD and resulting healthcare utilization patterns compared to the general population highlight the importance of studying DMD populations in detail. The epidemiology of DMD is expected to be generally similar globally, because there is no specific population with a known higher risk. However, variations may arise because of differences in study design and quality. As a result, pooled epidemiological estimates may be considered much more robust and reliable than estimates from single studies. Generating such epidemiological evidence on rare diseases like DMD is fundamental to evaluate the population impact of the disease in terms of burden of disease, to identify unmet clinical needs and to identify eligible target populations for drugs prior to their being marketed. The latter role of epidemiologic research is highlighted in the case of DMD since there are currently only two drugs specifically licensed for the treatment of DMD patients. Specifically, ataluren is licensed in Europe for the treatment of DMD patients with nonsense mutations, (approximately 10–15% of DMD cases) [8], while eteplirsen is licensed in the United States for the treatment of DMD patients who have a confirmed mutation that is amenable to exon 51 skipping (approximately 13% of DMD cases) [9]. This has an important impact on regulatory decisions including the decision to market a drug or not and important cost considerations such as whether a healthcare system is willing to pay for the drug or the adoption of managed entry agreements [10].

In the last 5 years, one narrative and two systematic literature reviews have summarized the global epidemiological evidence on muscular dystrophies [7, 11, 12]. In a recent review, evidence gaps have been highlighted particularly in prevalence and mortality [7] and the economic impact of this disease on healthcare systems is very high due to the needed multidisciplinary care and increases with disease progression, it is crucial to gather updated information on its prevalence, in order to ensure that resources and appropriate services are available for DMD patients world-wide. Moreover, the reviews only included studies up to 2015. This highlights the need to fill the four-year gap to provide updated information. Moreover, previous DMD epidemiology systematic reviews have pooled epidemiological data on DMD, but none of them have in addition performed the quality assessment of the included studies. In general, it is difficult to interpret the results of a study without evaluating its quality and this holds true specifically in rare diseases. The lack of an updated systematic review and meta-analysis which also evaluates study quality in order to aid the interpretation of the meta-analysis itself emerged clearly [11]. The aim of this study is therefore to update the previous systematic review and meta-analysis and to provide a quality assessment of the available epidemiological studies.


Literature search strategy and selection criteria

This systematic review and meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [13], the completed checklist can be found in the Additional file 1. The bibliographic databases MEDLINE and EMBASE were searched individually by two authors (SC, JS) for literature on the epidemiology of DMD from inception until the 1st October 2019. Both databases were searched for terms related to DMD, incidence, prevalence and epidemiology. Citations, titles and abstracts were exported into Endnote X9. The detailed literature search strategy for different databases is provided in Additional file 2.

Only original observational research articles which reported a numerical and well-defined measure of DMD occurrence, such as prevalence, birth prevalence and/or incidence of DMD and were written in English were included. No geographic exclusion criteria were imposed. Narrative or systematic reviews, meta-analyses, book chapters, editorials, personal opinions and conference abstracts were not included; however, the reference lists in reviews and meta-analyses were screened to potentially identify further studies to include. Studies were also excluded if they did not report the year in which the measure of occurrence was estimated. Information on the following items was collected: data source, study population, study years, study design, DMD outcomes description and measure of occurrence. Studies based on segregation analyses were not considered eligible for inclusion. Segregation analyses are methods that use statistical models to propose different hypotheses on the manner of biological inheritance, especially as a function on environmental factors. The epidemiological measures of frequency identified by these studies are therefore generally predicted, rather than actual, incidence or prevalence [14]. Only studies reporting the number of DMD cases as well as the underlying population were included in this analysis. If a study presented more than one estimate, the most recent one was used.

After removing duplicates from the two different databases, two review authors (SC, JS) individually screened the titles and abstracts of all records identified to remove articles that were clearly irrelevant; full text articles were then examined to determine whether they met the criteria for inclusion in the review. Any divergences were resolved through discussion or the intervention of a third review author (GT).

Data extraction and quality of study reporting assessment

Data were individually extracted from the included articles by two authors (SC and JS). The collected information included author(s), year of publication, study catchment area (i.e. geographic zone), data source (i.e. administrative databases, hospital and clinics medical reviews, surveys and other registries), study population (i.e. all living individual, patients and newborns), study period (i.e. the calendar years at which prevalence was measured), study design (i.e. cross-sectional, survey, prospective and retrospective cohorts or chart-review), DMD definition (i.e. ascertained by clinical examination, muscle biopsy and genetic screening) and the epidemiological estimate, i.e. the main outcome. All measures of DMD epidemiology identified in the articles were classified as either (overall) prevalence and birth prevalence. Prevalence was defined as the number of DMD cases identified at any time, including newly and non-newly diagnosed cases, in a source population potentially at risk prior to birth (i.e. all living persons in a well-defined catchment area), irrespective of age. Birth prevalence was defined as the number of DMD cases identified at birth, including only newly-diagnosed cases, in a source population potentially at risk prior to birth (i.e. all live births in the catchment area) [15]. Prevalence was calculated as the number of DMD cases divided by the individuals underlying the source population (and was multiplied by 100,000) and was distinguished between “point prevalence”, if estimated at a specific calendar year (i.e. the last study period year), and as “period prevalence” if estimated during the whole study period. Studies purporting to measure incidence were considered to constitute birth prevalence because this term is more fitting in the case of congenital anomalies, since the occurrence of congenital defects is often evaluated as a cumulative risk (e.g. number of events per 1000 persons), not as a rate of event occurrence per person-time among healthy individuals [16]. Such studies could include genetic screening at birth or other similar evaluations carried out on newborns and are likely to have higher epidemiological estimates compared to evaluations carried out later in life, as some patients may not have survived adulthood. These studies were therefore considered separately. The quality of study reporting was independently assessed by two reviewers (SC, JS) using a checklist adapted from STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) specifically for observational studies concerning rare diseases epidemiology [17].

Study quality was as classified as low, medium or high concerning the following five fields: description of study design and setting, description of eligibility criteria, study population, description of outcomes and description of the study participants. An overall score of low, medium and high was then assigned to each study. The full algorithm used to assign study quality is found in Additional file 3. Disagreements in score assignments were resolved through discussion or the intervention of a third review author (GT).

Statistical analysis

For each included study, the overall and birth prevalence of DMD per 100,000 individuals was considered as the primary outcome for the meta-analysis. All statistical analyses were performed on the logit-transformed prevalence (i.e. the logarithm of the prevalence divided by its complement) estimated within each study. Variance and its standard error (SE) were estimated applying the Delta-method on the normal approximation of the distribution of such transformed estimate [18]. The lower and upper bounds of each corresponding 95% confidence interval (95% CI) were calculated as the logit-transformed prevalence ±1.96 times SE and the 95% CI was further reported in its original scale by back transformation. As a subgroup analysis, the meta-analysis was stratified by study quality.

Between-study heterogeneity of epidemiological estimates was assessed using the Cochran’s Q-test [19] along with its derived measure of inconsistency (I2), and was considered to be present when Cochran’s Q-test p-value was < 0.10 or I2 > 40% [20]. Due to their dependence on the precision of included trials [21], I2 was also corroborated by its 95%CI calculated following the Q-profile method [22]. Study-specific outcomes were summarized by fixed-effects or random-effects logistic models, according to the absence or the presence of heterogeneity, respectively. In the latter case, meta-regression analyses were further performed to identify potential sources of heterogeneity (i.e. examining the contribution of different study-level covariates to the overall heterogeneity) and subgroups meta-analysis were also performed if necessary. The following variables were identified as potential sources of heterogeneity for further investigation: study design, the year in which the study started, study duration and the continent where the study was conducted. Examination of sources of heterogeneity was based on the statistical significance (from omnibus Wald-type test) evaluated to the examined variables. Moreover, the proportion of the between-studies variance which was explained by each study-level covariate was computed in terms of R2, which is defined as the ratio of the total between-studies variance explained by the study-level covariate to total between-studies variance computed from the random effects MA without the study-level covariate.

To investigate the presence of publication bias (which consists in the selective publication of studies in relation to their findings), a funnel plot showing the individual observed study outcome (on the x-axis) against the corresponding standard error (on the y-axis) was reported for each outcome at issue and the asymmetry of each funnel plot was evaluated by the rank correlation test, as proposed by Begg and Mazumdar [23]. It is generally accepted that when there are fewer than ten studies in a meta-analysis, both meta-regression [20] and test for publication bias [24] should not be considered.

Study-specific prevalence estimates (along with their 95% CI) as well as the overall summary prevalence estimate were graphically represented (in log scale) with a forest plot: for each study, ordered by the publication year, a square was plotted whose center projection corresponded to the study-specific estimate. A diamond was used to plot the overall prevalence, the center of which represents the point estimate whereas the extremes of the summary estimate show the 95% CI.

Two-sided p-values< 0.05 were considered for statistical significance. Statistical analyses were performed using SAS Software, Release 9.4 (SAS Institute, Cary, NC, USA) and R Foundation for Statistical Computing (version 3.6, package: metafor).


Study selection and characteristics

The flow-chart for study selection is shown in Fig. 1. Overall, the initial literature search identified 1951 studies. Following removal of duplicates (N = 520), 1431 abstracts were initially screened and only 57 (4.0%) full-text articles to review were retained for further evaluation. Of these, based on literature review, 44 (77.2%) studies containing information on the global epidemiology of DMD met the eligibility criteria and were therefore included in this systematic review. The detailed characteristics of the included studies are summarized in Table 1. Twenty-two studies (50%) reporting DMD prevalence [25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46] and 29 studies (65.9%) reporting DMD birth prevalence [25,26,27, 30, 34, 37, 39, 47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68] were included. Six studies (13.6%) reported both DMD prevalence and birth prevalence [25, 26, 30, 34, 37, 39]. The majority of the studies included (N = 28; 63.6%) were conducted in Europe. The geographical distribution of the studies included in the review is shown in Fig. 2. The studies conducted by Lefter et al., Norman et al., Leth et al. and Radhakrishnan et al. [27, 28, 46, 60] were excluded from the meta-analysis because the denominator used to calculate the prevalence was not reported in the full-text article.

Fig. 1

PRISMA flow-chart showing the process of literature search and study selection

Table 1 Characteristics of the included studies on Duchenne muscular dystrophy epidemiology
Fig. 2

Geographical distribution of the Duchenne muscular dystrophy epidemiological studies included in the systematic review

Quality of study reporting assessment

Overall, the quality of 44 studies was evaluated. In total 36 (81.8%) studies were assessed as being of medium and 8 (18.2%) being of low quality, while no study was assessed as having a high overall quality. Study design and setting were adequately reported in the majority of the studies included in this review (84.1%), while participants were adequately characterized only in 9.1% of the studies. On the contrary, the description of DMD identification was appropriate in 84.1% and unclear in 11.4% of the articles included. Figure 3 summarizes the overall quality of study reporting, which was estimated for all the 44 studies included. More detail about the quality of each included study is reported in Additional file 4.

Fig. 3

Quality of Duchenne muscular dystrophy epidemiological studies reporting assessment

Pooled DMD overall and birth prevalence

Of the 22 studies reporting DMD prevalence, 13 (59.1%) were European [25, 27, 30, 31, 33,34,35,36,37, 39, 41, 43, 46], 4 (18.2%) American [26, 42, 44, 45], 2 (9.1%) Asian [29, 38] and 3 (13.6%) were African [32, 40].

The majority of the studies evaluated DMD prevalence through secondary use of data such as clinical charts, administrative databases and patient or disease registries, apart from the study conducted by El-Tallawy et al. [40], which was based on a community survey. The global prevalence of DMD ranged from 0.9 [32] to 16.8 [36] cases per 100,000 males, including a population of neonates to the oldest surviving adults. When considering the general population (i.e. males and females), the global prevalence of DMD ranged from 0.7 to 7.7 cases per 100,000, with the lowest value in Sweden [31] and the highest value in Egypt [40]. The pooled DMD prevalence was 7.1 cases (95% CI: 5.0–10.1) per 100,000 males and 2.8 cases (95% CI: 1.6–4.6) per 100,000 persons (i.e. males and females together) (Fig. 4). A substantial heterogeneity was detected both in males (Cochran’s Q = 856.45, I2 = 98.5%, p < 0.001) and in the whole population (Cochran’s Q = 21.29, I2 = 87.4%, p < 0.001). The 95% CI for such I2 statistics were 97.2–99.4% and 63.0–99.4%, respectively. However, it is difficult to interpret these findings as heterogeneous on the basis of 5 studies only.

Fig. 4

Forest plot of the estimated Duchenne Muscular Dystrophy prevalence per 100,000 cases along with 95% confidence interval in studies which included (in the total population), among male individuals only and the ones which included male and female individuals, separately

Of the 29 studies reporting DMD birth prevalence, 21 (72.4%) were European [25, 27, 30, 34, 37, 39, 47, 51,52,53,54,55,56, 59,60,61,62,63,64, 67, 68], 4 (13.8%) were American [26, 58, 65, 66], 2 (6.9%) were Oceanian [49, 50] and 2 (6.9%) were Asian [48, 57] studies. The global birth prevalence of DMD range was very wide: from 1.5 to 28.2 cases per 100,000 live male births in Germany and Italy, respectively [25, 51, 68]. Eighteen studies (62.1%) [25,26,27, 30, 34, 37, 39, 47, 48, 50,51,52, 56, 57, 59, 61, 65, 68] were conducted using secondary data and 11 (37.9%) [49, 53,54,55, 58, 60, 62,63,64, 66, 67] using primary data collection, based on questionnaires, blood samples analysis, muscle biopsy and genetic screening. The pooled global birth prevalence was 19.8 cases (95% CI:16.6–23.6) per 100,000 live male births (Fig. 5). A substantial heterogeneity was seen among these studies (Cochrane’s Q = 82.03, I2 = 89.8%, p < 0.001) with a 95%CI for I2 ranging from 75.5 to 95.8%.

Fig. 5

Forest plot of the estimated Duchenne Muscular Dystrophy birth prevalence per 100,000 cases, along with 95% confidence interval

The stratification was only possible for medium quality studies (N = 36), because there were too few studies of low quality (N = 4) and no studies of high quality. The pooled estimate from random effects meta-analysis including all studies with medium quality was 6.8 (4.5–10.2) (I2 = 98.4%) and 19.5 (16.3–23.5) (I2 = 90.6%) concerning DMD prevalence and birth prevalence, respectively.

A visual inspection of the data suggested several outliers, namely Ballo et al. and Peterlin et al. who had very low values for prevalence per 100,000 males while and Darin et al. and Rasmussen et al. had very high values for this same outcome. However, no qualitative differences in study methodology to justify their impact on the pooled estimates were observed. Concerning birth prevalence, König et al. were found to be outliers. This study had problems with data collection in the last study year, as due to privacy issues, DMD cases were under-reported. No publication bias was found based on the funnel plot and Begg and Mazumdar’s rank correlation test for asymmetry both for DMD prevalence and birth prevalence (p-values = 0.771 and 0.184, respectively) (Fig. 6).

Fig. 6

Funnel plots for the estimated Duchenne Muscular Dystrophy (DMD) prevalence in males (panel a) and DMD birth prevalence (panel b) along with Begg and Mazumdar’s rank correlation test for asymmetry

Exploration of sources of heterogeneity

In order to explore the sources of heterogeneity of worldwide prevalence estimates, a meta-regression analysis was performed for DMD (males only) and birth DMD outcomes, separately. Meta-regression analysis was not performed in DMD general population because less than 10 studies were available. Since the point prevalence was estimated for almost all DMD studies whereas the period prevalence for almost all birth DMD studies, the information about prevalence type was not considered into the meta-regression analysis.

None of the study level covariates significantly reduced the between-study heterogeneity estimated from the random-effects meta-analysis (i.e. the proportion of explained heterogeneity R2 was always lower than 20%) with exception of the “study period” which significantly explained such heterogeneity between DMD birth prevalence study estimates (Wald-type test p < 0.001, R2 = 45%) although a high residual heterogeneity still remained (I2 = 83.1, 95%CI = 64.2–94.9%) (Table 2).

Table 2 Results of meta-regression analysis Duchenne Muscular Dystrophy (DMD) prevalence and birth prevalence


This systematic review provides an updated broad overview on the global epidemiology of DMD, including an evaluation of the quality of study reporting along with testing for publication bias. To our knowledge, this is the first comprehensive systematic review which evaluated the pooled global epidemiology of DMD. The pooled global prevalence and birth prevalence of DMD were 7.1 (95% CI: 5.0–10.1) and 19.8 (95% CI: 16.6–23.6) per 100,000 males, respectively. The birth prevalence is much higher than the prevalence because children with DMD may not survive beyond pediatric age likely in developing Countries with low adherence to standards of care. When considering as denominator the general population, the pooled global prevalence of DMD decreases, as expected, to 2.8 (95% CI: 1.6–4.6) cases per 100,000 as only males can be affected by the disease. Although epidemiological estimates were comparable in most studies, various outliers were found. The accuracy of these estimates could be strongly affected by different data sources (i.e. primary or secondary data), study design (e.g. prospective vs. retrospective studies, longitudinal vs. cross-sectional studies etc.), case definitions, inclusion criteria, sample sizes and DMD diagnostic methods, that could lead to extremely variable epidemiological estimations. In the present study we were not able to stratify results by ethnicity as this was not reported in all the studies; this might be important as it is known that some rare diseases such as Gaucher’s disease are known to be more common in specific ethnic groups, such as Ashkenazi Jews [69]. It was also not possible to compare the epidemiology across different countries, because of the small number of studies and large heterogeneity among the conducted studies.

Pooling the results of the different epidemiological studies, especially in the case of rare diseases, is particularly advantageous, since this increase of the total sample size allows more robust estimates and accounts for the potential differences among the included studies. Since the prevalence estimated within each included study was corroborated by a very small 95%CI (i.e. by a very small within-study variability or, in other words, by a very high precision) and since the I2 can be also expressed in terms of both the within-study variability (w) and the between-studies variability (b) components as follows: b/(w + b), it is clear that relatively small within-study variability will result in large I2 estimates (and this was the case) [21]. In response to this shortcoming, I2 estimates were also accompanied by their associated 95% CI [70, 71] because imprecise or biased estimates of heterogeneity can have serious consequences: for instance its overestimation may trigger inappropriate exploration of the cause(s) of heterogeneity. Nevertheless, such meta-analysis improves the accuracy and the reliability of the pooled estimate. The meta-regression analysis was useful to identify possible sources of heterogeneity by means of the use of study-level covariates. Interestingly, the only covariate which reduced the highest proportion of heterogeneity (about 45%) among DMD birth prevalence estimates was the year in which the study was carried out and its duration. The remaining heterogeneity could not be statistically accounted for.

Most studies included in this review were European, while only seven studies (15.9%) were identified from North America and no studies from South America were found. Overall, only 9 studies were found in Asia, Africa, Australia and New Zealand, all dated prior to 2005. Epidemiological research is essential to assess the population impact of rare diseases and to support public health decision-making: while epidemiological research can inform and improve public policy, public policy can also encourage and support epidemiological research. In Europe, rare diseases are among the priorities in public health research identified by the European Commission as of 2007 through FP7 programs and later through Horizon 2020 funding programs [72]. It may not be a coincidence that a review on public policy conducted in 2018 suggested that the European countries presented the most unified approach to rare diseases, while no rare disease policies were found in Africa, India and Russia [73].

The majority of the studies included used real-world data sources, such as claims databases, electronic medical records (EMRs) and patient/disease registries. Such data sources have a significant, and often under-used, potential to study rare diseases and to carry out accurate epidemiological evaluations [74]. The main advantage of using real-world data sources is the size of the catchment population, which is often very large, in the order of millions [75]. While this is an advantage in any research setting, it is particularly valuable to study rare diseases because the incidence of these diseases is so low.

However, there are also limitations to using each specific type of secondary data such as those from claims databases, EMRs and/or registries. One of the principal obstacles in using these data sources to study rare diseases is related to disease coding through systems such as International Classification of Diseases, 9th Revision (ICD-9), International Classification of Diseases, 10th Revision (ICD-10) and so on. While this is most relevant for claims and EHRs, some registries may also use ICD or similar codes [74].

Rare diseases commonly do not have a medical code specific to them. Taking DMD as an example, the ICD-9 code refers to muscular dystrophy in general, which includes but is not limited to DMD (ICD9-CM code: 359.1) [74]. Similarly, the ICD-10 code closest to DMD includes DMD but is not specific to it as it refers to Duchenne or Becker’s muscular dystrophy (ICD-10 code: G71.01). As a result, the specificity of the diagnosis in data systems that use these codes is not very high in DMD and in rare diseases with similar issues. One solution to this problem might be linking claims databases/electronic medical records to registers of rare diseases from the same catchment area, whenever available, to validate DMD diagnoses recorded in claims databases by comparing them to the gold standard diagnosis, i.e. the diagnosis in patient registers [74]. This approach was followed in the study conducted by König et al. [68], where DMD patients where identified through the linkage of clinical records and patient registers. However, even this approach has its limitations: the DMD prevalence measured in the study conducted by König et al. fell significantly (from 11.7 per 100,000 in 2014 to 1.5 per 100,000 in 2017) in the last few years of the study due to missing data as a result of privacy issues.

The role of patient registers in the published literature has been acknowledged as an important real-world data source on rare diseases for many years, although they have been underused because of barriers to data access. Registers provide a unique opportunity to follow the natural history of the disease in time [76]. The main limitation of registers with regards to the epidemiology of a rare disease is that the catchment area and its population (i.e. the denominator, whether in persons or person-years) may not be clearly defined. This would make it difficult to estimate the frequency of the diagnosis being made.

Apart from disease coding, another common tool for DMD identification in the studies included in the present review was genetic testing. Genetic testing for DMD is arguably the most reliable method of identifying DMD patients. There are at least three types of genetic tests available for DMD to date, i.e. tests for genetic duplications or deletions, CGH-array and direct sequencing. However, it is likely that quality of these tests increased over time. As a result, the reliability of DMD identification in earlier studies may not be as accurate as more recently conducted studies. In general, the identification of DMD patients in secondary data sources based on a diagnosis which is not directly associated with a genetic test is likely to be a less valid method than an identification method which is based primarily on genetic testing. However, the more accurate identification of true cases, for example, by genetic testing, does not necessarily lead to more accurate epidemiological estimates. Two studies which both used genetic testing to identify DMD reported much a higher prevalence per 100,000 males than the pooled estimate and were not consistent with other studies: Darin et al. [36] who reported a prevalence of 16.8 (95% CI: 11.8–23.8) and Rasmussen et al. [43], who reported a prevalence of 16.2 (95% CI: 11.4–22.9). The common elements between these two studies are the relatively low number of cases and the low number of persons in the source population, compared to other studies reporting the prevalence. These studies are more prone to over- or under-estimate the true number of cases based on a small sample size, even though they used genetic testing to identify DMD. This could in turn contribute to heterogeneity.

The overall quality of the studies, which reflects the transparency of reporting, included in the present review was assessed using a checklist adapted from STROBE. The results of the assessment suggest that the overall quality of study reporting was medium to low. In particular, although the majority of the studies adequately described the study design and setting, most of them did not report the eligibility criteria or an adequate characterization of the study participants (e.g. mean age, ethnicity). In some cases, this was in line with the research question of the studies, which did not address DMD alone but with other dystrophies [26,27,28,29, 32,33,34,35,36, 38, 40,41,42,43,44,45,46, 53, 56, 59, 61, 68]. Future studies should address the clinical picture of DMD patients on a large scale, as this is very informative concerning several aspects such as unmet clinical needs, overall survival and cost of care. The quality of reporting and the transparency in how the research was carried out are important because they impact how useful the study is [77]. This has been highlighted for observational research in epidemiology in general, but may be even more important for rare diseases, since the manner in which data is collected and the data analysis is carried out can potentially lead to a very large variability of results due to the very small sample size. An additional problem that follows is that it becomes very difficult to replicate studies. From the present paper, it is clear that the transparency of reporting of observational studies concerning DMD needs to improve significantly.

Strengths and limitations

The main strengths of our systematic review and meta-analysis are the exhaustive literature search strategy and the double review process as well as the inclusion of studies published very recently. Meta-regression analysis is another strength of this study, which allowed us to identify the main drivers of heterogeneity. Moreover, we restricted the meta-analysis for medium quality studies, in order to have an estimate that is not affected by low-quality studies. Nevertheless, the stratified meta-analysis was in line with the main results.

However, several limitations should be considered. We have tried to describe the studies in as much detail as possible, including the heterogeneity among them. The quality of our analyses could be affected by the intrinsic limitations of each included article and the different DMD outcome definitions of the individual studies could compromise the internal validity of this meta-analysis. Furthermore, although no publication bias was found, the between-studies heterogeneity was very high. Moreover, we were not able to stratify our results by ethnicity as this was not reported in all the studies.


To our knowledge, this is the first systematic review to evaluate the pooled global epidemiology of DMD and to assess the quality of study reporting. Due to the wide differences between each study (e.g. study design and setting, study population, data sources, case ascertainment, etc.) DMD prevalence and birth prevalence estimates are variable throughout the literature, ranging 0.9 to 16.8 per 100,000 males from 1.5 to 28.2 per 100,000 live male births, respectively. The pooled prevalence and birth prevalence were 5.3 (95% CI: 5.1–5.5) cases per 100,000 males and 21.4 (95% CI: 20.4–22.5) cases per 100,000 live male births respectively. Generating epidemiological evidence on DMD is fundamental to support public health decision-making in allocating resources considering the high disease’s costs related to the need of multidisciplinary care, the elevated direct and indirect burden of patients and caregivers and the recently available expensive therapies. The overall quality of epidemiological studies on DMD was relatively low, highlighting the need for high quality studies in this field. High quality studies with more transparent reporting are required to better understand the epidemiology of DMD.

Availability of data and materials

Systematic review and meta-analysis performed on already published papers. The databases used to conduct this study and the PRISMA flow diagram are included in the main text and the detailed literature search strategy is reported in the supplementary materials.



Duchenne Muscular Dystrophy


STrengthening the Reporting of OBservational studies in Epidemiology


Creatinine kinase


Duchenne/Becker muscular dystrophy

95% CI:

95% confidence interval


Attention Deficit Hyperactivity Disorder


Preferred Reporting Items for Systematic Reviews and Meta-Analyses


Standard error

I2 :



Electronic medical records


International Statistical Classification of Diseases and Related Health Problems, 8th edition


International Classification of Diseases, 9th Revision


International Classification of Diseases, 10th Revision


Multiplex ligation-dependent probe amplification


Degrees of freedom




  1. 1.

    Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Glob Health. 2018;4422(18).

  2. 2.

    Giliberto F, Radic CP, Luce L, Ferreiro V, de Brasi C, Szijan I. Symptomatic female carriers of Duchenne muscular dystrophy (DMD): genetic and clinical characterization. J Neurol Sci. 2014;336(1–2):36–41 Available from:

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347–61.

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926–9.

    PubMed  Article  Google Scholar 

  5. 5.

    Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, et al. Managing Duchenne muscular dystrophy - the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord. 2007;17(6):470–5.

    PubMed  Article  Google Scholar 

  6. 6.

    Hendriksen JGM, Vles JSH. Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J Child Neurol. 2008;23(5):477–81.

    PubMed  Article  Google Scholar 

  7. 7.

    Ryder S, Leadley RM, Armstrong N, Westwood M, De Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–98.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Food and Drug Administration. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. 2016. Available from:

    Google Scholar 

  10. 10.

    Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2014;16(1):1–3.

    Article  Google Scholar 

  11. 11.

    Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482–91.

    PubMed  Article  Google Scholar 

  12. 12.

    Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43(3-4):259–68.

    PubMed  Article  Google Scholar 

  13. 13.

    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

  14. 14.

    Jarvik GP. Complex segregation analyses: uses and limitations. Am J Hum Genet. 1998;63(4):942–6 Available from:

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Prevention C for DC. Updated National birth prevalence estimates for selected birth defects in the United States, 2004–2006. Available from: Accessed 1 Oct 2019.

  16. 16.

    Cornel MC. Common language for measures of occurrence of congenital anomalies and genetic diseases: incidence or birth prevalence. Community Genet. 1999;2(4):162–4.

    CAS  PubMed  Google Scholar 

  17. 17.

    Leadley RM, Lang S, Misso K, Bekkering T, Ross J, Akiyama T, et al. A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases. Orphanet J Rare Dis. 2014;9:173.

    PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974–8.

    PubMed  Article  Google Scholar 

  19. 19.

    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

  20. 20.

    Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collab; 2011. Available from:

  21. 21.

    Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  Google Scholar 

  22. 22.

    Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 2007;26(1):37–52.

    PubMed  Article  Google Scholar 

  23. 23.

    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.

    Article  PubMed  Google Scholar 

  25. 25.

    Danieli GA, Mostacciuolo ML, Bonfante A, Angelini C. Duchenne muscular dystrophy - a population study. Hum Genet. 1977;35(2):225–31.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Monckton G, Hoskin V, Warren S. Prevalence and incidence of muscular dystrophy in Alberta, Canada. Clin Genet. 2008;21(1):19–24.

    Article  Google Scholar 

  27. 27.

    LETH A, WULFF K, CORFITSEN M, ELMGREEN J. Progressive muscular dystrophy in Denmark. Acta Paediatr. 1985;74(6):881–5.

    CAS  Article  Google Scholar 

  28. 28.

    Radhakrishnan K, El-Mangoush MA, Gerryo SE. Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. Acta Neurol Scand. 1987;75(2):95–100.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Nakagawa M, Nakahara K, Yoshidome H, Suehara M, Higuchi I, Fujiyama J, et al. Epidemiology of progressive muscular dystrophy in Okinawa, Japan. Neuroepidemiology. 1991;10(4):185–91.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    van Essen AJ, Busch HFM, te Meerman GJ, ten Kate LP. Birth and population prevalence of Duchenne muscular dystrophy in the Netherlands. Hum Genet. 1992;88(3):258–66.

    PubMed  Article  Google Scholar 

  31. 31.

    Ahlström G, Gunnarsson LG, Leissner P, Sjödén PO. Epidemiology of neuromuscular diseases, including the postpolio sequelae, in a Swedish county. Neuroepidemiology. 1993;12(5):262–9.

    PubMed  Article  Google Scholar 

  32. 32.

    Ballo R, Viljoen D, Beighton P. Duchenne and Becker muscular dystrophy prevalence in South Africa and molecular findings in 128 persons affected. S Afr Med J. 1994;84(8 Pt 1):494–7.

    CAS  PubMed  Google Scholar 

  33. 33.

    Hughes MI, Hicks EM, Nevin NC, Patterson VH. The prevalence of inherited neuromuscular disease in Northern Ireland. Neuromuscul Disord. 1996;6(1):69–73.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Peterlin B, Zidar J, Meznarič-Petruša M, Zupančič N. Genetic epidemiology of Duchenne and Becker muscular dystrophy in Slovenia. Clin Genet. 1997;51(2):94–7.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Siciliano G, Tessa A, Renna M, Manca ML, Mancuso M, Murri L. Epidemiology of dystrophinopathies in North-West Tuscany: a molecular genetics-based revisitation. Clin Genet. 1999;56(1):51–8.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord. 2000;10(1):1–9.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977-2001: Prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord. 2003;13(10):804–12.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Chung B, Wong V, Ip P. Prevalence of neuromuscular diseases in Chinese children: a study in Southern China. J Child Neurol. 2003;18(3):217–9.

    PubMed  Article  Google Scholar 

  39. 39.

    Talkop ÜA, Kahre T, Napa A, Talvik I, Sööt A, Piirsoo A, et al. A descriptive epidemiological study of Duchenne muscular dystrophy in childhood in Estonia. Eur J Paediatr Neurol. 2003;7(5):221–6.

    PubMed  Article  Google Scholar 

  40. 40.

    El-Tallawy HN, Khedr EM, Qayed MH, Helliwell TR, Kamel NF. Epidemiological study of muscular disorders in Assiut, Egypt. Neuroepidemiology. 2005;25(4):205–11.

    PubMed  Article  Google Scholar 

  41. 41.

    Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132(11):3175–86.

    PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Mah J, Selby K, Campbell C, Nadeau A, Tarnopolsky M, McCormick A, et al. A population-based study of dystrophin mutations in Canada. Can J Neurol Sci. 2011;38(3):465–74.

    PubMed  Article  Google Scholar 

  43. 43.

    Rasmussen M, Risberg K, Vøllo A, Skjeldal OH. Neuromuscular disorders in children in south-eastern Norway. J Pediatr Neurol. 2012;10(2):95–100.

    Google Scholar 

  44. 44.

    Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GKD, et al. Prevalence of duchenne and becker muscular dystrophies in the United States. Pediatrics. 2015;135(3):513–21.

    PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Ramos E, Conde JG, Berrios RA, Pardo S, Gómez O, Mas Rodríguez MF. Prevalence and genetic profile of Duchene and Becker muscular dystrophy in Puerto Rico. J Neuromuscul Dis. 2016;3(2):261–6.

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88(3):304–13.

    PubMed  Article  Google Scholar 

  47. 47.

    Brooks AP, Emery AEH. The incidence of Duchenne muscular dystrophy in the South East of Scotland. Clin Genet. 1977;11(4):290–4.

    CAS  PubMed  Google Scholar 

  48. 48.

    Takeshita K, Yoshino K, Kitahara T, Nakashima T, Kato N. Survey of duchenne type and congenital type of muscular dystrophy in Shimane, Japan. Jpn J Hum Genet. 1977;22(1):43–7.

    CAS  Article  Google Scholar 

  49. 49.

    Drummond LM. Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy. Arch Dis Child. 1979;54(5):362–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Cowan J, MacDessi J, Stark A, Morgan G. Incidence of Duchenne muscular dystrophy in New South Wales and the Australian Capital Territory. J Med Genet. 1980;17(4):245–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Danieli GA, Mostacciuolo ML, Pilotto G, Angelini C, Bonfante A. Duchenne muscular dystrophy - data from family studies. Hum Genet. 1980;54(1):63–8.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Bertolotto A, De Marchi M, Doriguzzi C, Mongini T, Monnier C, Palmucci L, et al. Epidemiology of Duchenne muscular dystrophy in the province of Turin. Ital J Neurol Sci. 1981;2(1):81–4.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Nigro G, Comi LI, Limongelli FM, Giugliano MAM, Politano L, Petretta V, et al. Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve. 1983;6(4):253–62.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Dellamonica C, Collombel C, Cotte J, Addis P. Screening for neonatal Duchenne muscular dystrophy by bioluminescence measurement of creatine kinase in a blood sample spotted on paper. Clin Chem. 1983;29(1):161–3.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Scheuerbrandt G, Lundin A, Lövgren T, Mortier W. Screening for duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve. 1986;9(1):11–23.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Mostacciuolo ML, Lombardi A, Cambissa V, Danieli GA, Angelini C. Population data on benign and severe forms of X-linked muscular dystrophy. Hum Genet. 1987;75(3):217–20.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Takeshita K, Kasagi S, Mito T, Tanaka T, Ootani K. Decreased incidence of duchenne muscular dystrophy in western Japan 1956-1980. Neuroepidemiology. 1987;6(3):130–8.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Greenberg CR, Jacobs HK, Nylen E, Rohringer M, Averill N, Van Ommen GJB, et al. Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening. Lancet. 1988;332(8608):425–7.

    Article  Google Scholar 

  59. 59.

    Tangsrud S-E, Halvorsen S. Child neuromuscular disease in Southern Norway: prevalence, age and distribution of diagnosis with special reference to “non-Duchenne muscular dystrophy”. Clin Genet. 1988;34(3):145–52.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Norman AM, Rogers C, Sibert JR, Harper PS. Duchenne muscular dystrophy in Wales: a 15 year study, 1971 to 1986. J Med Genet. 1989;26(9):560–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Merlini L, Bonfiglioli Stagni S, Marri E, Granata C. Epidemiology of neuromuscular disorders in the under-20 population in Bologna province, Italy. Neuromuscul Disord. 1992;2(3):197–200.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Bradley DM, Parsons EP, Clarke AJ. Experience with screening newborns for Duchenne muscular dystrophy in Wales. Br Med J. 1993;306(6874):357–60.

    CAS  Article  Google Scholar 

  63. 63.

    Drousiotou A, Ioannou P, Georgiou T, Mavrikiou E, Christopoulos G, Kyriakides T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test. 1998;2(1):55–60.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Eyskens F, Philips E. G.P.10 10 Newborn screening for Duchenne muscular dystrophy. The experience in the province of Antwerp. Neuromuscul Disord. 2006;16(9):721.

    Article  Google Scholar 

  65. 65.

    Dooley J, Gordon KE, Dodds L, MacSween J. Duchenne muscular dystrophy: a 30-year population-based incidence study. Clin Pediatr (Phila). 2010;49(2):177–9.

    Article  Google Scholar 

  66. 66.

    Mendell JR, Shilling C, Leslie ND, Flanigan KM, Al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for duchenne muscular dystrophy. Ann Neurol. 2012;71(3):304–13.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet. 2013;21(10):1049–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  68. 68.

    König K, Pechmann A, Thiele S, Walter MC, Schorling D, Tassoni A, et al. De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany. Orphanet J Rare Dis. 2019;14(1):152.

    PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet. 1991;49:855–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Ioannidis JPA. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951–7.

    PubMed  Article  Google Scholar 

  71. 71.

    Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335(7626):914–6.

    PubMed  PubMed Central  Article  Google Scholar 

  72. 72.

    European Commisson. Commission activities in the area of Rare diseases. Available from:

  73. 73.

    Khosla N, Valdez R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. Intractable Rare Dis Res. 2018;7(4):213–22.

    PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Crisafulli S, Sultana J, Ingrasciotta Y, Addis A, Cananzi P, Cavagna L, et al. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opin Drug Saf. 2019;18(6):497–509.

    PubMed  Article  Google Scholar 

  75. 75.

    Trifirò G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug Saf. 2018;41(2):143–9.

    PubMed  Article  Google Scholar 

  76. 76.

    McGettigan P, Alonso Olmo C, Plueschke K, Castillon M, Nogueras Zondag D, Bahri P, et al. Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf. 2019;42(11):1343–51.

    PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Harper S. A future for observational epidemiology: clarity, credibility, transparency. Am J Epidemiol. 2019;188(5):840–5.

    PubMed  Article  Google Scholar 

Download references


We thank the Medical Department of PTC Therapeutics Italia for its unrestricted support for the editorial aspects of this paper.


This study was funded with unconditional grant from PTC Therapeutics Italia.

Author information




GT and SM were responsible for the conception and design of the study and reviewed the manuscript. SC and JS reviewed the articles, conducted the systematic review and drafted the manuscript. AF performed the statistical analyses. FS reviewed and revised the draft manuscript. All authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Gianluca Trifirò.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

G. Trifirò has served on advisory boards for Sandoz, Hospira, Sanofi, Biogen, Ipsen, and Shire and is a consultant for Otsuka. G Trifirò is the principal investigator of observational studies funded by several pharmaceutical companies (e.g. Amgen, AstraZeneca, Daiichi Sankyo and IBSA) to University of Messina, as well as scientific coordinator of the Master’s program ‘Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real-world data evaluations’ at University of Messina, which is partly funded by several pharmaceutical companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Crisafulli, S., Sultana, J., Fontana, A. et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 15, 141 (2020).

Download citation


  • Duchenne muscular dystrophy
  • Epidemiology
  • Prevalence
  • Birth prevalence
  • Systematic review
  • Meta-analysis